Independent evidence resource

Ibogaine Research Digest: Studies, Summarised

A plainspoken guide to what studies of ibogaine do—and do not—show for people researching In F in Ig a in E, with safety and evidence quality kept in view.

Reflective research setting for an evidence-focused overview of ibogaine studies

Start with the scope

Why this research matters—and why caution remains essential

Ibogaine is a long-acting psychoactive indole alkaloid derived from the root bark of the West African iboga shrub. It is metabolized partly into noribogaine, a pharmacologically active metabolite with a longer half-life and a distinct receptor profile.

Where studies focus

Human clinical and observational research has concentrated on opioid use disorder, opioid withdrawal, PTSD, alcohol use and other substance-use conditions.

What remains unknown

No randomized, placebo-controlled trial has established ibogaine’s efficacy. Observational findings cannot fully separate expectancy, selection bias, intensive aftercare or regression to the mean.

What safety changes

Cardiac toxicity, especially QT prolongation and malignant arrhythmias, remains the central development barrier. The clinical context for QT prolongation is therefore fundamental to interpreting every claimed benefit.

Study explorer

Read the evidence in distinct layers

The links below group the major questions people bring to ibogaine research. Each category is a different kind of evidence, not a verdict on treatment.

Clinical and observational findings

Signals are worth studying; they are not proof of efficacy.

Research has described rapid changes in withdrawal, craving, mood or trauma-related symptoms after a single administration. One review summary reports an approximately 80% reduction in Addiction Severity Index scores, from 0.32 to 0.06, alongside acute withdrawal improvement with p = 0.015.

Those figures are hypotheses-generating rather than definitive. A recent clinical research review helps place these findings beside the limitations of small, uncontrolled and context-dependent studies. Earlier framing can also be found in a review chapter on ibogaine, which describes a broad but uneven evidence base.

Close-up research detail accompanying the review of ibogaine evidence

Development and regulation

Formal trials are changing the question

Ibogaine has moved from largely underground experimentation toward formal federal drug development. In 2026, reported activity includes early-phase trial design questions about dose escalation, eligibility, safety monitoring and stopping rules.

A planned IBO-CARE study is described as screening up to 120 candidates and enrolling 60 adults with moderate-to-severe opioid use disorder across three cohorts of 20, with a planned participant age range of 18–65 years. Its projected primary completion is July 1, 2027, with planned study completion January 31, 2029.

Readers can compare these developments with the NHS research summary for oral ibogaine in opioid users and the policy analysis of the emerging ibogaine landscape.

For a focused account of trauma-related research, Stanford Medicine’s report on ibogaine and PTSD study results is useful context, but it does not replace controlled efficacy research. The U.S. clinical trial registry is the appropriate place to check current study status and protocol details.

Safety lens

Potential and risk must be read together

Ibogaine research is consequential because the potential upside and development risk are inseparable. This is not an established therapy, and this page does not provide dosing instructions or endorse unsupervised use.

Cardiac toxicity is the central barrier

Ibogaine can prolong QTc and trigger torsades de pointes, ventricular tachycardia, ventricular fibrillation and cardiac arrest. The FDA’s discussion of QT-related rhythm risk illustrates why medication-associated electrical changes require careful clinical attention.

Pharmacology does not establish clinical benefit

Ibogaine and noribogaine have different receptor profiles and time courses. A concise compound profile for ibogaine can help orient readers to this distinction, while the broader reference overview of ibogaine provides basic historical and chemical context.

Commercial and underground contexts are not equivalent to trials

Traditional, underground and commercial treatment settings can involve very different screening, monitoring, aftercare and reporting practices. Claims drawn from published treatment-results data should therefore be distinguished from randomized evidence.

How to weigh a claim

Use study design as the filter

The research question is not simply whether a result sounds promising. It is whether the study can show that ibogaine, rather than context or bias, caused the outcome.

Ask what was compared

Without randomization, a placebo or an appropriate comparison group, strong outcome changes may still reflect selection effects, expectations, concurrent care or the natural course of symptoms.

Ask what was monitored

Eligibility criteria, medication interactions, ECG monitoring, stopping rules and adverse-event reporting matter as much as any symptom score when evaluating ibogaine research.

Ask what happened later

Short-term withdrawal or mood changes do not establish durable outcomes. Follow-up duration, retention and aftercare shape how a study should be interpreted.

“Promising observational findings have not yet been separated from expectancy effects, selection bias, intensive aftercare or regression to the mean.”

For readers seeking practical orientation rather than treatment advice, Infinigaine’s approach to independent evidence review explains the standards behind these summaries. The site’s research-navigation resources are designed to help people frame questions about evidence, safety, legality and practical considerations without making clinical claims.

Historical and popular accounts, including Discover Magazine’s account of ibogaine and addiction, can be useful background. They should be read separately from protocol-level study evidence and safety reporting.

Is ibogaine an established treatment?

No. Ibogaine remains clinically unproven: no randomized, placebo-controlled trial has established its efficacy, and it is not an approved medical treatment in the United States. A comprehensive overview of published studies can help show the breadth of material, but evidence quality still determines what can be concluded.

Why are accounts of the experience not the same as evidence?

Experience reports can describe subjective effects, but they cannot demonstrate efficacy, safety or generalizability. A descriptive overview of the reported ibogaine experience belongs in a different category from prospective clinical research.

What is the central safety concern?

Cardiac toxicity is the central development barrier. QTc prolongation and serious rhythm disturbances are the reason study eligibility, medical screening, monitoring and stopping rules are central—not peripheral—to research interpretation.

What should readers look for in a study?

Look for study design, participant selection, comparison groups, safety monitoring, follow-up duration, aftercare and transparent adverse-event reporting. For wider drug-development context, the NIDA overview of medications for opioid use disorder clarifies why rigorous clinical evidence matters in this field.

Evidence-first orientation

Research is moving. Certainty has not arrived.

Use this digest as a starting point for careful questions about ibogaine’s research status, safety constraints and evidence gaps.

View the evidence summary

For further context, see ibogainetreatmentfordepression.com.